# EDGAR Filing Document

**Accession Number:** 0001828318
**File Stem:** 0001828318-25-000223
**Filing Date:** 2025-7
**Character Count:** 22690
**Document Hash:** f5496bab8e38d56b29ec3d7d02afab0f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001828318-25-000223.hdr.sgml**: 20250707

**ACCESSION NUMBER**: 0001828318-25-000223

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250707

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250707

**DATE AS OF CHANGE**: 20250707

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enovix Corp
- **CENTRAL INDEX KEY:** 0001828318
- **STANDARD INDUSTRIAL CLASSIFICATION:** MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 853174357
- **FISCAL YEAR END:** 1228

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39753
- **FILM NUMBER:** 251107054

**BUSINESS ADDRESS:**
- **STREET 1:** 3501 W. WARREN AVENUE
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538
- **BUSINESS PHONE:** 510 695-2350

**MAIL ADDRESS:**
- **STREET 1:** 3501 W. WARREN AVENUE
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Rodgers Silicon Valley Acquisition Corp
- **DATE OF NAME CHANGE:** 20201014

?xml version='1.0' encoding='ASCII'? envx-20250707

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON**, **D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 7, 2025**

**Enovix Corporation**

![Capture.jpg](envx-20250707_g1.jpg)

**(Exact Name of Registrant as Specified in Its Charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39753** | **85-3174357** |
| (State or Other Jurisdiction<br>of Incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **3501 W Warren Avenue** <br>**Fremont, California** | **94538** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**Registrant's Telephone Number, Including Area Code: (510) 695-2350** 

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading <br>Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | ENVX | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On July 7, 2025, Enovix Corporation (the "Company") issued a press release announcing preliminary selected unaudited financial results for the second fiscal quarter of 2025. The full text of the press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

The information in this item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 7.01 Regulation FD Disclosure.**

The information furnished as Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | <br>**Description** |
| 99.1 | <u>[Q2 2025](envx8k-q32025x772025ex991.htm)[Preliminary](envx8k-q32025x772025ex991.htm)[Financial Results Press Release dated](envx8k-q32025x772025ex991.htm)[July](envx8k-q32025x772025ex991.htm)[7](envx8k-q32025x772025ex991.htm)[, 2025.](envx8k-q32025x772025ex991.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | | **Enovix Corporation** |
| Date: | July 7, 2025 | By: | /s/ Arthi Chakravarthy |
|  |  |  | Arthi Chakravarthy<br>Chief Legal Officer and Head of Corporate Development |

---

## Exhibit 99.1

**Exhibit 99.1**![capturea.jpg](capturea.jpg)

**Enovix Announces Preliminary Second Quarter 2025 Financial Results**

*Q2 Revenue Exceeds High-End of Guidance, Up 98% Year Over Year*

**FREMONT, Calif., July 7, 2025** -- Enovix Corporation (Nasdaq: ENVX) ("Company" or "Enovix"), a global high-performance battery company, today announced **preliminary selected unaudited financial results for the second quarter ended June 29, 2025**:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Revenue** was **$7.5 million** in the second quarter of 2025, **exceeding our guidance range** of $4.5 million to $6.5 million and **nearly doubled** from the second quarter of 2024, driven by customer demand across multiple end markets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **GAAP Gross Profit** was **$0.8 million** and **non-GAAP Gross Profit** was **$1.2 million,** marking our **third consecutive quarter of positive gross profit** on both a GAAP and non-GAAP basis. This compares favorably to a gross loss of $0.7 million on a GAAP basis and gross loss of $0.6 million on a non-GAAP basis in the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **GAAP Operating Loss** was **$43.8 million** and **non-GAAP Operating Loss** was **$27.8 million, beating our guidance range** of $31 to $37 million and compared to $88.8 million on a GAAP basis and $31.5 million on a non-GAAP basis in the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **GAAP Net Loss Attributable to Enovix** was **$43.3 million,** improved from the $115.9 million in the second quarter of 2024. **Non-GAAP Net Loss Attributable to Enovix** was **$28.4 million,** as compared to the $24.9 million in the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Adjusted EBITDA Loss** narrowed to **$21.4 million**, **ahead of our guidance range** of $23 million to $29 million, and improved from the $26.4 million in the same period a year ago.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **GAAP net loss per share attributable to Enovix** was **$0.22** and **non-GAAP net loss per share attributable to Enovix** was **$0.15**, at the **favorable end of our guidance range** of $0.15 to $0.21 per share and compared to $0.67 on a GAAP basis and $0.14 on a non-GAAP basis in the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Cash, cash equivalents, and short-term investments** were approximately **$203 million** as of the quarter ended June 29, 2025, after completing the SolarEdge asset acquisition in South Korea and making other capital expenditure payments principally related to Fab2.

"This marks our **fifth straight quarter exceeding the midpoint of guidance for both revenue and adjusted EBITDA,**" said Dr. Raj Talluri, Chief Executive Officer. "We're executing to plan, building momentum, and positioned to scale significantly as our new products and customers come online."

Preliminary and unaudited financial results are provided above and below. Final results remain subject to completion of the company's standard quarter-end close procedures and potential adjustments. Enovix will host its Q2 2025 earnings call and webcast in late July or early August and details will be announced separately.

------

**About Enovix**

Enovix is on a mission to deliver high-performance batteries that unlock the full potential of technology products. Everything from IoT, mobile, and computing devices, to the vehicle you drive, needs a better battery. Enovix partners with OEMs worldwide to usher in a new era of user experiences. Our innovative, materials-agnostic approach to building a higher performing battery without compromising safety keeps us flexible and on the cutting-edge of battery technology innovation.

Enovix is headquartered in Silicon Valley with facilities in India, South Korea and Malaysia. For more information visit https://enovix.com and follow us on LinkedIn.

**Non-GAAP Financial Measures**

Non-GAAP Gross Profit, non-GAAP Operating Loss, Adjusted EBITDA, non-GAAP net loss attributable to Enovix, non-GAAP net loss per share, and other non-GAAP measures are intended as supplemental financial measures of our performance that provide an additional tool for investors to use in evaluating ongoing operating results, trends, and in comparing our financial measures with those of comparable companies.

However, you should be aware that other companies may calculate similar non-GAAP measures differently. Non-GAAP financial measures have limitations, including that they exclude certain expenses that are required under GAAP, which adjustments reflect the exercise of judgment by management. Reconciliations of each non-GAAP financial measure to the most directly comparable GAAP financial measure can be found in the tables at the end of this press release.

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and can be identified by words such as anticipate, believe, continue, could, estimate, expect, intend, may, might, plan, possible, potential, predict, preliminary, project, setting the stage, should, would and similar expressions that convey uncertainty about future events or outcomes. Forward-looking statements in this press release include, without limitation, our expected performance and preliminary financial results for the second quarter of 2025, including, without limitation, with respect to our second quarter 2025 revenue, GAAP and non-GAAP Gross Profit, GAAP and non-GAAP net operating loss, EBITDA and adjusted EBITDA, GAAP and non-GAAP net loss per share attributable to Enovix, and GAAP and non-GAAP earnings per share attributable to Enovix, as well our expectations regarding building momentum, and positioning to scale significantly as our new products and customers come online.

Actual results could differ materially from these forward-looking statements as a result of certain risks and uncertainties, including, without limitation, any adjustments, changes or revisions to our financial results arising from our financial closing procedures and the completion of our financial statements for the second quarter of 2025; our ability to improve energy density, cycle life, fast charging, capacity roll off and gassing metrics among our products; our reliance on new and complex manufacturing processes for our operations; our ability to establish sufficient manufacturing operations and improve and optimize manufacturing processes to meet demand, source materials and establish supply relationships, and secure adequate funds to execute on our operational and strategic goals; our reliance on a manufacturing agreement with a Malaysia-based company for many of the facilities, procurement, personnel and financing needs of our operations; our operation in international markets, including our exposure to operational, financial and regulatory risks, as well as risks relating to geopolitical tensions and conflicts, including changes in trade policies and regulations; that we may be required to pay costs for components and raw materials that are more expensive than anticipated, including as a result of trade barriers, trade sanctions, export restrictions, tariffs, embargoes or shortages and other general economic and political conditions, which could delay the introduction of our products and negatively impact our business; our ability to adequately control the costs associated with our operations and the components necessary to build our lithium-ion battery cells; our lengthy sales cycles; the safety hazards associated with our

------

batteries and the manufacturing process; a concentration of customers in the military market and our dependence on these customer accounts; certain unfavorable terms in our commercial agreements that may limit our ability to market our products; our ability to develop, market and sell our batteries, expectations relating to the performance of our batteries, and market acceptance of our products; our ability to accurately estimate the future supply and demand of our batteries, which could result in a variety of inefficiencies in our business; changes in consumer preferences or demands; changes in industry standards; the impact of technological development and competition; and global economic conditions, including tariffs, inflationary and supply chain pressures, and political, social, and economic instability, including as a result of armed conflict, war or threat of war, or trade and other international disputes that could disrupt supply or delivery of, or demand for, our products. For additional information on these risks and uncertainties and other potential factors that could cause actual results to differ from the results predicted, please refer to our filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our annual report on Form 10-K and quarterly reports on Form 10-Q and other documents that we have filed, or will file, with the SEC.

The financial results presented herein are preliminary and based on information known by management as of the date of this press release; final financial results will be included in the Company's quarterly report on Form 10-Q for the fiscal quarter ended June 29, 2025. As a result, the financial results presented in this press release may change in connection with the finalization of our closing and reporting processes and may not represent the actual financial results for the second quarter ended June 29, 2025. Any forward-looking statements in this press release speak only as of the date on which they are made. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

**Contacts:**

**Investors**

Robert Lahey

ir@enovix.com

**Chief Financial Officer**

Ryan Benton

ryan.benton@enovix.com

------

**Reconciliation of Gross Profit to Non-GAAP Gross Profit**

Below is a reconciliation of GAAP gross profit to non-GAAP gross profit (preliminary and unaudited) (in thousands).

---

| | | |
|:---|:---|:---|
| | **Fiscal Quarters Ended** | **Fiscal Quarters Ended** |
| | **June 29, 2025** | **June 30, 2024** |
| **GAAP gross profit** | $795 | $(655) |
| Stock-based compensation expense | 356 | 95 |
| **Non-GAAP gross profit** | $1151 | $(560) |

---

**Net Loss Attributable to Enovix to Adjusted EBITDA Reconciliation**

While we prepare our consolidated financial statements in accordance with GAAP, we also utilize and present certain financial measures that are not based on GAAP. We refer to these financial measures as "non-GAAP" financial measures. In addition to our financial results determined in accordance with GAAP, we believe that EBITDA and Adjusted EBITDA are useful measures in evaluating its financial and operational performance distinct and apart from financing costs, certain non-cash expenses and non-operational expenses.

These non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP but should not be considered a substitute for or superior to GAAP. We endeavor to compensate for the limitation of the non-GAAP financial measures presented by also providing the most directly comparable GAAP measures.

We use non-GAAP financial information to evaluate our ongoing operations and for internal planning, budgeting and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors in assessing its operating performance and comparing its performance with competitors and other comparable companies. You should review the reconciliations below but not rely on any single financial measure to evaluate our business.

"EBITDA" is defined as earnings (net loss) attributable to Enovix adjusted for interest expense, income tax benefit, depreciation and amortization expense. "Adjusted EBITDA" includes additional adjustments to EBITDA such as stock-based compensation expense, change in fair value of common stock warrants, inventory step-up, impairment of equipment and other special items as determined by management which it does not believe to be indicative of its underlying business trends.

------

Below is a reconciliation of net loss attributable to Enovix on a GAAP basis to the non-GAAP EBITDA and Adjusted EBITDA financial measures for the periods presented below (preliminary and unaudited) (in thousands):

---

| | | |
|:---|:---|:---|
| | **Fiscal Quarters Ended** | **Fiscal Quarters Ended** |
| | **June 29, 2025** | **June 30, 2024** |
| Net loss attributable to Enovix | $(43347) | $(115872) |
| &nbsp;&nbsp;&nbsp;Interest income, net | (599) | (1635) |
| &nbsp;&nbsp;&nbsp;Income tax benefit |  | (4586) |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 8855 | 5943 |
| EBITDA | (35091) | (116150) |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense <sup>(1)</sup> | 14121 | 17932 |
| &nbsp;&nbsp;&nbsp;Change in fair value of common stock warrants | 5885 | 33660 |
| &nbsp;&nbsp;&nbsp;Acquisition cost | 663 |  |
| &nbsp;&nbsp;&nbsp;Gain on bargain purchase of assets | (6944) |  |
| &nbsp;&nbsp;&nbsp;Restructuring cost <sup>(1)</sup> |  | 38146 |
| Adjusted EBITDA | $(21366) | $(26412) |

---

<sup>(1)</sup> $1.1 million of stock-based compensation expense is included in the restructuring cost line of the table above for the fiscal quarter ended June 30, 2024.

**Reconciliation of Operating Loss to Non-GAAP Operating Loss and Adjusted EBITDA**

Additionally, below is a reconciliation of GAAP operating loss to non-GAAP operating loss and adjusted EBITDA for the periods presented (preliminary and unaudited) (in thousands).

These non-GAAP measures may differ from similarly titled measures used by other companies.

---

| | | |
|:---|:---|:---|
| | **Fiscal Quarters Ended** | **Fiscal Quarters Ended** |
| | **June 29, 2025** | **June 30, 2024** |
| GAAP Operating Loss | $(43750) | $(88750) |
| Stock-based compensation expense <sup>(1)</sup> | 14121 | 17932 |
| Amortization of intangible assets | 1189 | 1189 |
| Acquisition cost | 663 |  |
| Restructuring cost <sup>(1)</sup> |  | 38146 |
| Non-GAAP Operating Loss | (27777) | (31483) |
| Depreciation and amortization (excluding amortization of intangible assets) | 7666 | 4754 |
| Other income (loss), net | (993) | 242 |
| Net loss (income) attributable to non-controlling interest | (261) | 75 |
| Adjusted EBITDA | $(21365) | $(26412) |

---

<sup>(1)</sup> $1.1 million of stock-based compensation expense is included in the restructuring cost line of the table above for the fiscal quarter ended June 30, 2024.

------

**Reconciliation of Non-GAAP Net Loss Attributable to Enovix and Non-GAAP Net Loss Per Share Attributable to Enovix** 

Below is a reconciliation of GAAP net loss attributable to Enovix to non-GAAP net loss attributable to Enovix for the periods presented (preliminary and unaudited) (in thousands).

These non-GAAP measures may differ from similarly titled measures used by other companies.

---

| | | |
|:---|:---|:---|
| | **Fiscal Quarters Ended** | **Fiscal Quarters Ended** |
| | **June 29, 2025** | **June 30, 2024** |
| **GAAP net loss attributable to Enovix** | $(43347) | $(115872) |
| Stock-based compensation expense <sup>(1)</sup> | 14121 | 17932 |
| Change in fair value of common stock warrants | 5885 | 33660 |
| Amortization of intangible assets | 1189 | 1189 |
| Acquisition cost | 663 |  |
| Gain on bargain purchase of assets | (6944) |  |
| Restructuring cost <sup>(1)</sup> |  | 38146 |
| **Non-GAAP net loss attributable to Enovix shareholders** | $(28433) | $(24945) |
| **GAAP net loss per share attributable to Enovix, basic and diluted** | $(0.22) | $(0.67) |
| GAAP weighted average number of common shares outstanding, basic and diluted | 192675756 | 172399172 |
| **Non-GAAP net loss per share attributable to Enovix, basic and diluted** | $(0.15) | $(0.14) |
| GAAP weighted average number of common shares outstanding, basic and diluted | 192675756 | 172399172 |

---

<sup>(1)</sup> $1.1 million of stock-based compensation expense is included in the restructuring cost line of the table above for the fiscal quarter ended June 30, 2024.